Ahead of the World Tobacco Congress, Dr. Alan Blum and Cancer Network have partnered to assemble a four-part slideshow series addressing the history of America’s smoking pandemic. Part 1 examines the early evidence linking smoking with cancer.
This slide show includes some of the top highlights from the 2015 ASCO Genitourinary Cancers Symposium, including a study that examined the risk of aggressive prostate cancer in testicular cancer survivors and more.
This slide show highlights recent studies that examined coffee consumption as it relates to cancer risk, including melanoma, breast and liver cancers, and more.
This slide show includes some of the highlights from the 2015 ASCO Gastrointestinal Cancers Symposium, including a study that linked vitamin D levels to colorectal cancer outcomes, positive results in pancreatic cancer with a new targeted agent, and more.
In this slide show we present some of the top cancer stories of 2014, including a newly discovered gene that confers a high-risk of breast cancer and the impressive survival improvement with the addition of docetaxel to ADT in newly diagnosed metastatic prostate cancer.
This slide show highlights the 2014 FDA approvals of cancer treatments, which included therapies for melanoma and lung, gastric, ovarian, and cervical cancers, as well as various hematologic malignancies.
This slide show features some of the top highlights from the 2014 San Antonio Breast Cancer Symposium, including ovarian suppression in ER-positive breast tumors, tamoxifen for disease prevention, and immunotherapies for triple-negative breast cancer.
This slide show features some of the top highlights on immunotherapies and other new agents in leukemia and lymphoma from the 2014 ASH Meeting.
With evidence from a number of studies, this presentation delves into the controversy surrounding the treatment, or overtreatment, of ductal carcinoma in situ (DCIS), and discusses whether or not these lesions should indeed be classified as breast cancer.
This slide show reports on a pooled analysis that found up to a fivefold risk of second cancers among smokers, compared with cancer survivors who never smoked.